Lilly announced the establishment of its China medical innovation center in the Beijing Economic-Technological Development Area (Beijing E-Town) on Oct 15, to promote clinical research and accelerate the drug development process.

This is another multinational pharmaceutical company innovation center to be located in BioPark of Beijing E-Town following Pfizer's establishment of a legal entity in the area.

As a leading enterprise in the global pharmaceutical and health industry, Lilly has consistently regarded China as a strategic focus since entering the Chinese market in 1918. The company has continuously deepened its presence in China, maintaining a leading position in areas such as diabetes and obesity, oncology, immunology, and neuroscience.

In China, Lilly has established a complete layout across the entire industry chain, including research and development, production, promotion, support services, and reinvestment.

The Lilly China Medical Innovation Center is dedicated to enhancing clinical trial efficiency, supporting drug registration reviews, and accelerating cutting-edge research on innovative drugs to benefit patients.

Dr. Daniel Skovronsky, chief scientific officer of Lilly and president of Lilly Research Laboratories as well as Lilly's Immunotherapy Division, highlighted that the establishment of the Lilly China Medical Innovation Center and Lilly Innovation Incubator in Beijing will further deepen Lilly's century-long presence in China. The new center will empower the company to explore novel clinical research designs to accelerate patients' access to breakthrough therapies.

As the host location of the Lilly China Medical Innovation Center, Beijing E-Town is becoming a hotbed for the aggregation of pharmaceutical and health enterprises due to its well-established industrial chain and superior business environment.

At present, Beijing E-Town has attracted nearly 5,000 pharmaceutical and health enterprises, covering the entire industrial chain including drugs, medical devices, and services. The pharmaceutical and health manufacturing industry accounts for nearly half of the city's total, making it the most concentrated area for the development of the pharmaceutical and health industry in Beijing.

Moving forward, Beijing E-Town will further create favorable conditions for multinational pharmaceutical companies like Lilly to land and develop here.